TY - JOUR
T1 - Effect of octreotide on gastrostomy, duodenostomy, and cholecystostomy effluents
T2 - A physiologic study of fluid and electrolyte balance
AU - Niv, Y.
AU - Charash, B.
AU - Sperber, A. D.
AU - Oren, M.
PY - 1997/11
Y1 - 1997/11
N2 - Objectives: Octreotide, a somatostatin analog, reduces stool and fistula outputs by a mechanism that is not completely understood. Our aim was to study its effect on gastrostomy, duodenostomy, and cholecystostomy effluents in a patient with colorectal cancer. Methods: Effluents of gastrostomy, duodenostomy, and cholecystostomy were collected in three separate shifts over 24-h periods beginning 3 days before octreotide therapy and continuing for 15 treatment days. Fifty-four samples were tested for volume, pH, acid, and bicarbonate production, and biochemical profiles. Results: A positive fluid balance was achieved immediately with octreotide therapy. Significant decreases in gastrostomy and duodenostomy outputs and in gastric acid production were observed (1433.33 ± 33.33 ml/24 h to 535.71 ± 55.31 ml/24 h, p < 0.0001; 2066.67 ± 66.67 ml/24 h to 247.14 ± 36.04 ml/24 h, p < 0.0001; and 67.50 ± 3.20 mEq/h to 13.00 ± 1.50 mEq/h, p < 0.0001; respectively). Gastrostomy tachyphylaxis was observed after 6 days of treatment. Remarkable dose-dependent increases were found in cholesterol and bilirubin concentrations in the cholecystostomy effluent. Conclusions: Octreotide's primary effect is a decrease in gastric and pancreatic secretions. The increased concentrations of cholesterol and bilirubin may explain the occurrence of gallstones in patients treated with octreotide.
AB - Objectives: Octreotide, a somatostatin analog, reduces stool and fistula outputs by a mechanism that is not completely understood. Our aim was to study its effect on gastrostomy, duodenostomy, and cholecystostomy effluents in a patient with colorectal cancer. Methods: Effluents of gastrostomy, duodenostomy, and cholecystostomy were collected in three separate shifts over 24-h periods beginning 3 days before octreotide therapy and continuing for 15 treatment days. Fifty-four samples were tested for volume, pH, acid, and bicarbonate production, and biochemical profiles. Results: A positive fluid balance was achieved immediately with octreotide therapy. Significant decreases in gastrostomy and duodenostomy outputs and in gastric acid production were observed (1433.33 ± 33.33 ml/24 h to 535.71 ± 55.31 ml/24 h, p < 0.0001; 2066.67 ± 66.67 ml/24 h to 247.14 ± 36.04 ml/24 h, p < 0.0001; and 67.50 ± 3.20 mEq/h to 13.00 ± 1.50 mEq/h, p < 0.0001; respectively). Gastrostomy tachyphylaxis was observed after 6 days of treatment. Remarkable dose-dependent increases were found in cholesterol and bilirubin concentrations in the cholecystostomy effluent. Conclusions: Octreotide's primary effect is a decrease in gastric and pancreatic secretions. The increased concentrations of cholesterol and bilirubin may explain the occurrence of gallstones in patients treated with octreotide.
UR - http://www.scopus.com/inward/record.url?scp=0030668965&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 9362203
AN - SCOPUS:0030668965
SN - 0002-9270
VL - 92
SP - 2107
EP - 2111
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 11
ER -